Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. 
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INTRODUCTION
Affibody molecules are a class of small (7 kDa) scaffold proteins, which are composed of a 3-helix cysteine-free bundle consisting of 58 amino acids [1] . Affibody molecules can be selected to bind different proteins with high affinity by randomization of thirteen amino acids on helices 1 and 2 [2] . Their small size facilitates high rates of extravasation and tissue penetration, and rapid blood clearance of unbound tracer molecules [3] . High-affinity Affibody molecules have been selected for binding to cancer-associated molecular targets such as HER2 (human epidermal growth factor receptor type 2) [4] , EGFR (epidermal growth factor receptor) [5] , HER3 (human epidermal growth factor receptor type 3) [6] , PDGFRplatelet derived growth factor receptor  [7] and IGF1R (insulin-like growth factor 1 receptor) [8] . Preclinical studies, including direct comparison experiments, have demonstrated that Affibody molecules provide higher imaging contrast than radiolabeled antibodies [9, 10] , and clinical studies have confirmed high potential for Affibody molecules in molecular imaging [11, 12] The binding surface of Affibody molecules localizes only on helices 1 and 2, while helix 3 provides stability to the structure. In principle, helix 3 might be removed if the scaffold rigidity could be provided by other means [13] . In order to develop a 2-helix Affibody molecule targeting HER2, the previously described Affibody molecules named Z HER2:342, and a 2-helix version of the IgG-binding Z domain, denoted Z34C, were used as design templates [4, 13] . Webster and co-workers [14] have shown that introduction of a disulfide bridge between the C-and N-termini stabilizes the 2-helix structure and permits peptide synthesis of 2-helix Affibody molecules with retained binding specificity to HER2, although at a cost of substantial reduction of affinity (3 orders of magnitude). Further optimization of the sequence and the use of homocysteine for disulfide bridge formation allowed obtaining a 2-helix Affibody variant with affinity of 5 nM [14] . Although this affinity is appreciably lower than the affinity of parental Affibody molecules Z HER2:342 (22 pM, [4] ), it is still sufficient for imaging applications [15] . A DOTA-conjugated 2-helix variant, DOTA-MUT-DS (other designation PEP09239), has previously been labeled with 68 Ga, 64 Cu and 111 In, and successfully used for imaging of HER2-expressing tumor xenografts in mice [16] [17] [18] . Direct in vivo comparison of the biodistribution properties of 111 In-PEP09239 and its parental 3-helix Affibody molecule 111 In-ABY-002 [4] showed that although the absolute tumor uptake values were higher for the 3-helix variant, the 2-helix variant showed higher tumor-to-blood ratio [18] . The results of these studies suggest that novel and robust disulfide-stabilized 2-helix scaffolds are promising molecular probes for imaging applications. However, these variants have unprotected termini, which make them potentially sensitive to exoproteases.
Furthermore, the disulfide bond in their structure restricts selection of labeling methods. The use of methods requiring the use of strong reducing agents (e.g. labeling with 99m Tc) might be complicated.
Recently, we have developed an alternative approach to stabilization of 2-helix Affibody molecules based on backbone cyclization by native chemical ligation (NCL) [19] . This approach was applied to the parental IgG-binding Affibody molecule (the Z-domain) resulting in a new format denoted Z min . In this study, the loss of affinity in comparison with its 3-helix parental variant was modest, from K D = 3 to 15 nM. The backbone cyclization by NCL leaves a cysteine residue at the ligation point between helices 1 and 2, and this residue might be used as a chemo-selective handle for conjugation of chelators and linkers for radionuclides.
This strategy eliminates the risk of thiol-disulfide exchange or reduction of the disulfide.
Other advantageous properties of a smaller 2-helix scaffold, such as possible higher tissue penetration, are preserved in this design.
In the current study, we applied NCL for development of a 2-helix anti-HER2 Affibody molecule. When removing the stabilizing third helix from the Affibody scaffold, the hydrophobic core of the scaffold is exposed to the environment and specific mutations must be introduced in helices 1 and 2 in order to retain protein solubility. Braisted et al. preformed a thorough step-wise selection of random mutations to produce a soluble, high-affinity 2-helix version of the Z-domain [20] . We applied the described substitutions, in combination with substitutions introduced to facilitate synthesis of a backbone-cyclized version of the Z-domain to the HER2-binding Z HER2:342 Affibody molecules (for sequence, see Figure 1D ). The resulting 2-helix Affibody molecule is a combination between the previously published sequences of Z34C [20] and Z HER2:342 [11] and was designated Z HER2:342min. The Z HER2:342min molecule was evaluated in terms of affinity, selectivity and thermal stability. After sitespecific conjugation with maleimido-DOTA, the Z HER2:342min was labeled with radionuclides and HER3 (ErbB3) were from R&D Systems, MN, USA.
Buffers, such as 0.1 M phosphate-buffered saline (PBS), pH 7.5, and 0.2 M ammonium acetate, pH 5.5, and 1.25 M sodium acetate, pH 3.6, were prepared using high-quality Milli-Q water (resistance higher than 18 MΩ cm). Metal contamination was removed from the buffers used for labeling by purification using 2-3 g/l Chelex 100 resin (Bio Rad Laboratories, Richmond, CA, USA). PEP09239 was produced as described earlier [18] . to confirm the identity of 68 Ga-DOTA-Z HER2:342min . The distribution of radioactivity along the thin layer chromatography strips and electrophoresis gels was measured on a Cyclone storage phosphor system and analyzed using OptiQuant image analysis software. The radioactivity was measured using an automated gamma-counter with a 3-inch NaI (Tl) detector (1480 Wizard; Wallac Oy, Turku, Finland).
Data on cellular uptake and biodistribution were analyzed by two-tailed t-test using GraphPad Prism (version4.00 for Windows; GraphPad Software, San Diego, CA) in order to determine the significance of differences (p<0.05). benzimidazolinone (Nbz) in order to form a C-terminal ester as performed earlier [19] .
Briefly, 4-nitrophenylchloroformate (5 eq.) in DCM was added (40 min) to the peptide-resin for specific acylation, followed by deprotonation and cyclization of the linker with 0.5 M DIEA in DCM [28] .
Cleavage from the solid support was performed using a standard Fmoc protocol. Briefly, the peptide-resin was treated for 2 h at room temperature with a cleavage solution consisting of TFA/EDT/H 2 O/TIS (94:2.5:2.5:1). Cleavage from the solid phase was followed by three rounds of extraction with tert-butyl methyl ether and H 2 O (3:1), and the aqueous phase was then filtered, frozen, and lyophilized.
Purification and Analysis of Z HER2:342min
The linear peptide was purified and analyzed by Reversed Phase High Performance Liquid Chromatography (RP-HPLC) (Agilent Technologies) with an elution gradient of 35-55% acetonitrile-0.1%TFA for 20 min at a flow rate of 2.5 ml/min on a 10 mm×250 mm C18 column with 5 µm particle size (semi preparative, Reprosil Gold 300, Dalco Chromtech AB).
The collected fractions were frozen and lyophilized. The theoretical molecular weight of the peptide was calculated from its molecular formula C 186 H 291 N 57 O 56 S 2. The peptide mass was confirmed by ESI-MS (6520 Accurate Mass Q-TOF LC/MS, Agilent Technologies), coupled to RP-HPLC using a 300 µm×5 mm C4 column, particle size 5 µm (Acclaim PepMap300, LC Packings -Genetech). The concentration of the peptide was determined by absorbance measurements using Eppendorf BioPhotometer (Eppendorf) and the concentration was calculated using Beer-Lambert's law (extinction coefficient=8480 M -1 cm -1 ).
Cyclization and Purification of Z HER2:342min
Backbone cyclization of the peptide was carried out over 2 h using the ligation buffer Na 2 HPO 4 /MPAA/TCEP (0.2 M: 0.2 M: 0.02 M), pH 7. Purification of the cyclized product was performed by semi-preparative RP-HPLC using a gradient of 35-55% acetonitrile-0.1%TFA, at a flow rate of 2.5 ml/min with the same column and solvent system as described above for the linear peptide. Up to three repetitive rounds of RP-HPLC purification were required in order to remove all the excess of MPAA from the cyclization step.
DOTA Conjugation
5 equivalents of maleimido-DOTA (Macrocyclics) were coupled to the free Z HER2:342min cysteine residue in a 5 mM NaOAc buffer, pH 5.5, for 2 h at room temperature. DOTA-Z HER2:342min (PEP12718) was then purified by RP-HPLC and the conjugation was confirmed by ESI-MS as described above.
Circular Dichroism Analysis
The helicity of DOTA-Z HER2:342min was investigated by Circular Dichroism (CD). The CD spectra were collected using a Jasco J-810 spectropolarimeter (Jasco Scandinavia AB), and recorded in 0.1 nm intervals over a 190-250 nm spectra in a 0.1 cm quartz cell at 20°C.
Peptide concentration was 0.5 mg/ml. The melting temperature was determined over a heat gradient (20-90˚C) at 220 nm. To study refolding of DOTA-Z HER2:342min , the helical content was measured for a second time after heat treatment. All CD spectra represent an average of three assembled scans.
Surface Plasmon Resonance Analysis of Binding Kinetics
Surface M citric acid, pH 2.0. In this system, radiolabelled proteins remain at the application point while free 111 In migrates with the solvent front. PEP09239 was labeled with 111 In for comparative biodistribution and kinetic interaction experiments as described previously [18] .
For labeling with 68 Ga, the generator was eluted with 0. The stability of 111 In-DOTA-Z HER2:342min and 68 Ga-DOTA-Z HER2:342min was evaluated by challenge with 500-fold excess of EDTA during 1 h as described earlier [21] .
Measurements of Affinity of 2-Helix Affibody Molecules Binding to Living HER2-Expressing Cells using LigandTracer Yellow
Cells from the human ovarian carcinoma cell line SKOV-3 were seeded on a local area of a cell culture dish (NunclonTM, Size 100620, NUNC A/S, Roskilde, Denmark), as described previously [22] . The binding of 111 In-DOTA-Z HER2:342min and 68 Ga-DOTA-Z HER2:342min to living cells was monitored in real-time at room temperature using LigandTracer Yellow, using established methods [22] . In brief, the cell culture dish was placed on the sloping and rotating cell dish holder in LigandTracer Yellow, followed by a continuous monitoring of the radioactivity level along the rim of the dish. If the labeled Affibody molecule binds to the cells, an elevated signal will be recorded when the cells pass by the detector. This makes it possible to accurately detect binding events both during incubation and after wash [22] . In order to cover the concentration span needed for proper affinity estimation entirely, two 
Comparative In Vivo Studies
The goal of the study was a comparative evaluation of 68 Ga and 111 In influence on the biodistribution and targeting properties of DOTA-Z HER2:342min . All animal experiments were planned and performed in accordance with the national regulation on laboratory animals' protection and were approved by the local Ethics Committee for Animal Research in Uppsala.
In order to reduce the number of animals in the experiments, a dual-label approach was used when both 68 Ga-and 111 In-labelled tracers were co-injected in the same mice. and subtracted from counts obtained during first measurement (immediately after dissection).
The resulted values presented radioactivity of 68 Ga in each organ during the first measurement. These values were used to calculate biodistribution of 68 Ga-labeled tracer.
As a comparator for DOTA-Z HER2:342min , an additional biodistribution study on the same animal batch with the same xenograft model was performed using 111 In-and 68 Ga-labeled PEP09239. A group of four mice were injected intravenously (tail vein) with 3.51 µg, 10 kBq ( 111 In-PEP09239) and 380 kBq ( 68 Ga-PEP09239), in 100 µL PBS per animal and the biodistribution of the radioactivity was measured as described above.
RESULTS

Production, Purification and Identification of DOTA-Z HER2:342min
Purity of the backbone-cyclized peptide was confirmed by ESI-MS (Molecular formula: 
Helicity and Thermal Stability of DOTA-Z HER2:342min
CD spectroscopy was used to confirm that the cyclic DOTA-Z HER2:342min adopted a helical structure. As expected, the spectra showed the characteristics of α-helical structure with minima at 208 and 220 nm and a maximum between 194 and 196 nm (Figure 2 ). When No exact transition temperature could be estimated since the conversion was gradual (data not shown). When cooled down to ambient temperature, the protein adopted the same helical structure as prior to heat treatment (Figure 2 ).
Affinity and Selectivity of DOTA-Z HER2:342min towards HER2
Analysis of the binding kinetics showed that DOTA-Z HER2:342min has high affinity towards its target receptor with a determined dissociation constant K D of 18 nM (Figure 3) . No interaction with the negative control was detected, suggesting that DOTA-Z HER2:342min is selective for its target (data not shown). The affinity of the 2-helix DOTA-Z HER2:342min
Affibody variant for binding to HER2 is approximately 10 3 times lower than the affinity of the corresponding, original 3-helix Affibody molecule. This is in line with data reported earlier on other 2-helix versions of HER2-binding 3-helix Affibody molecules [16] [17] [18] .
Radiolabeling of Conjugates with 111
In and 68 Ga
Radiochemical yields of 98.75 ± 3.4% and 99.7 ± 0.0% were achieved for 111 In-DOTA-Z HER2:342min and 111 In-PEP09239 with specific activities of about 0.8 MBq/µg (3.9 GBq/µ mol).
The labeling yield was lower than standard value (≥95%), when adding 80 MBq of 68 Ga. It can be due to the higher amount of impurity in the eluted fraction. Decreasing the activity to 40 MBq improved the yield considerably; analytical radiochemical yield was 92.2 ± 1.9%
(specific activity about 2 MBq/µg, 9.6 GBq/µmol) and 97.1 ± 0.3% (specific activity about 0.8 MBq/µg, 3.9 GBq/µmol) for 68 Ga-DOTA-Z HER2:342min and 68 Ga-PEP09239, respectively.
Identity of 68 Ga-DOTA-Z HER2:342min was confirmed using SDS-PAGE (Figure 4) .
The EDTA challenge demonstrated very high labeling stability. The radiochemical purity of 68 Ga-DOTA-Z HER2:342min after challenge with 500-fold EDTA excess was 98.3±0.4% and 99.2±0.3%, for EDTA-treated samples and control samples, respectively. The radiochemical purity of 111 In-DOTA-Z HER2:342min was 98.3±0.3% and 98.9±0.1%, for EDTA-treated samples and control samples, respectively.
In Vitro Binding Property Evaluation of Labeled Conjugates
The kinetics measurements of 2-helix Affibody molecules binding to HER2-expressing SKOV-3 cells in vitro using LigandTracer confirmed that antigen-binding capacity was preserved after labeling. The sensorgrams are presented on Figure 5 . (Figure 5) . The presence of strong and weak interactions was also found for the three other radioconjugates ( 
In Vivo Biodistribution Studies
Data concerning targeting of HER2-expressing SKOV-3 xenografts in BALB/c nu/nu mice using 68 Ga-DOTA-Z HER2:342min and 111 In-DOTA-Z HER2:342min at 1 h and 2 h post injection are presented in Figure 6 , 7, and 8. Pre-saturation of HER2 receptors in tumor xenografts using non-labeled Z HER2:342 Affibody molecule reduced the tumor uptake of both 68 Ga-DOTA-Z HER2:342min and 111 In-DOTA-Z HER2:342min significantly (Figure 6) , which confirms the specificity of the radioconjugates' binding to HER2 in vivo. Biodistribution studies demonstrated rapid blood clearance of both radioconjugates (Figure 7) . Radioactivity in the gastrointestinal tract with content was low (less than 2% of injected radioactivity), which suggests that hepatobiliary excretion played only a minor role in the elimination of radiolabeled Z HER2:342min . More apparent was renal excretion with subsequent tubular reabsorption, as kidney uptake was more than 150% ID/g for both radioconjugates. between tumor uptake at 1 and 2 hours after injection was not significant for both conjugates.
Tumor-to-blood, and tumor-to-muscle, tumor-to-lung, and tumor-to-bone ratios were significantly higher for 111 In-DOTA-Z HER2:342min at 1 and 2 h after injection (Figure 8) . 111 In-PEP09239 and 68 Ga-PEP09239 were used as comparators for 111 In-DOTA-Z HER2:342min and 68 Ga-DOTA-Z HER2:342min . One group of tumor-bearing animals from the same batch was used to study biodistribution of 111 In-PEP09239 and 68 Ga-PEP09239 at 1 h after injection ( Table 2 ). The data for biodistribution of 111 In-PEP09239 were in a good agreement with previous studies [18] .
111
In-PEP09239 and 68 Ga-PEP09239 provided approximately four-fold higher radioactivity uptake in tumors. Besides, uptake of 111 In-DOTA-Z HER2:342min and 68 Ga-DOTA-Z HER2:342min was appreciably higher in lungs, liver and spleen. Tumor-to-blood, tumorto-liver, and tumor-to-spleen ratios were higher for PEP09239.
DISCUSSION
Developing of molecular imaging has substantial potential in identifying and characterization of disease-specific biomarkers. Imaging of these biomarkers holds great promise to better define treatment, stratify patients and evaluate therapeutic response [23] . When choosing an appropriate targeting agent for molecular imaging, scaffold proteins with high proteolytic stability, resistance to elevated temperatures, and long-term shelf life as well as fast kinetics are considered as one of the best options [24] . The Affibody scaffold, a 58 amino acid residue domain, has been extensively used as a targeting agent in several studies for therapeutic and diagnostic purposes. The relatively small number of amino acid residues in the scaffold enables synthesis of Affibody molecules by solid phase peptide synthesis (SPPS).
Chemical synthesis in turn makes it possible to modify or add specific moieties to the scaffold in a convenient way. Decreasing the size of Affibody molecules might give rise to advantageous properties, such as better solubility, improved tissue penetration, more rapid clearance of non-bound tracer and comparatively low production costs. Previous studies [16] [17] [18] have proven that truncated 2-helix Affibody scaffolds display faster in vivo kinetics than their 3-helix variants. Although tumor uptake of these 2-helix scaffolds decreased appreciably in comparison with the parental 3-helix variant, tumor-to-organ ratios increased significantly due to elevated clearance of non-bound tracers. The lower tumor uptake of 2-helix variants can be explained by lower affinity and lower bioavailability of the radioconjugates due to the faster blood clearance. Since tumor-to-organ and especially tumor-to-blood ratios are important parameters in image contrast, development of 2-helix scaffolds is an interesting approach to obtaining the high contrast molecular imaging even if the tumor uptake is lower.
The use of NCL for stabilization of the structure of 2-helix Affibody molecules offers a number of potential advantages, such as potentially higher resistance to exopeptidases, possibility to perform labeling in the presence of strong reducing or oxidizing agents, and possibility of site-specific labeling using thiol-directed chemistry. However, Z HER2:342min differs appreciably from the previously described variant (MUT-DS, PEP09239). A total of 10 amino acid were deleted or substituted, and Z HER2:342min is shorter than PEP09239 (35 aa vs 39 aa). In addition, different chemistry was used for conjugation of the DOTA chelator. Earlier experience with Affibody molecules has suggested that even smaller changes in composition (substitution of one to three amino acids) could cause appreciable differences in biodistribution, such as the level of hepatic uptake [25, 26] or percentage of hepatobiliary excretion [27] [28] [29] . Moreover, coupling of different nuclides using the same chelator could cause differences in organ uptake and blood clearance rate of Affibody molecules [21, 29, 30] .
This necessitated careful characterization of the new Z HER2:342min variant both in vitro and in
vivo.
The engineered 2-helix Affibody Z HER2:342min showed a preserved specificity of binding to HER2. The affinity toward its target (18 nM, as measured using Biacore) (Figure 3 ) was substantially decreased in comparison with the parental 3-helix Z HER2:342 Affibody molecule (22 pM) [4] . However, previous studies have demonstrated that low nanomolar affinity of Affibody molecules is suitable for imaging of abundantly expressed HER2 [4, [15] [16] [17] [18] 31] .
Importantly, the structure of DOTA-Z HER2:342min was completely restored after heat treatment (Figure 2) , which is essential as the labeling using DOTA requires elevated temperatures.
DOTA-Z HER2:342min was successfully labeled with 111 In (for imaging using SPECT) and 68 Ga (for imaging using PET) with retained binding capacity. In vitro studies with HER2-expressing cells using LigandTracer indicated that interaction of tracers with receptors could be described by two different binding affinities ( Table 1) : one nanomolar affinity and one substantially lower. It is important to point out that the difference between affinity values measured using Biacore and LigandTracer can be explained by the difference of the methods.
Biacore evaluates the binding kinetics using an artificial system with immobilized receptors, while LigandTracer assays are performed on living cells. Previously it has been shown that ligands binding to the HER family receptors on living cells display various kinetics and affinity characteristics [32, 33] . Presence of other HER family members as well as activation processes due to the homo-and hetero-dimerization of the receptors [34] might affect the binding kinetics and affinity. The difference in ligand interaction kinetics with the same overexpressed receptor in different cell lines has previously been demonstrated using
LigandTracer [35] . Biphasic binding of 3-helix Affibody molecules to living cell lines has been found earlier using LigandTracer [33] . Interestingly, affinity of 111 In-labeled variants was higher than 68 Ga-labeled for both DOTA-Z HER2:342min and PEP09239. It has to be noted that 68 Ga and 111 In complexes of DOTA have different geometry [36] , which influences structure and affinity of labeled peptides.
In vivo, both 68 Ga-DOTA-Z HER2:342min and 111 In-DOTA-Z HER2:342min were able to specifically target HER2-expressing SKOV-3 xenografts (Figure 6 ). 0.5% ID/g at 1 h, were in the same range [31] . Blood clearance of 2-helix DOTA-Z HER2:342min was significantly faster than 3-helix monomeric and dimeric Affibody molecules. At 2 h after injection, the tumor-to-blood ratios were 4.6 ± 0.7 and 6.1 ± 0.5 for 68 Ga-DOTA-Z HER2:342min and 111 In-DOTA-Z HER2:342min , respectively. This is the level the best antibody-based HER2-imaging agents display 2-3 days after injection [37] .
The dual label approach permitted to reveal different influence of 111 In and 68 Ga on the biodistribution properties of DOTA-Z HER2:342min . The blood clearance rate of 111 In-DOTA-Z HER2:342min was higher, which resulted in significantly lower blood concentration 1 h after injection. At 2 h after injection, the uptake of 68 Ga-DOTA-Z HER2:342min was significantly higher in lung and spleen, but lower in liver and kidneys in comparison to 111 In-DOTA-Z HER2:342min (Figure 7) . The tumor uptake was slightly, but significantly higher for 111 In-DOTA-Z HER2:342min . In general, 111 In-DOTA-Z HER2:342min provided higher tumor-to-blood, tumor-to-spleen, tumor-to-muscle, and tumor-to-bone ratios (Figure 8 ). (Table 2) , which can be explained by the higher affinities of PEP09239-based tracers ( Table 1 ). The major issue is, however, that uptake of DOTA-Z HER2:342min is appreciably higher in liver, spleen and lung ( Table 2) . This makes tumor imaging problematic, as liver and lungs are metastatic sites for many malignancies.
Higher uptake in lung, liver and spleen of radiolabeled DOTA-Z HER2:342min compared to radiolabeled PEP09239 might be due to different reasons. In principle, uptake in these organs might be specific. However, a numerous studies with parental Z HER2:343 and its derivatives having the same binding site have demonstrated that uptake in these organs is not saturable, and therefore nonspecific [40] [41] [42] [43] [44] . Much lower uptake was also for radiolabeled PEP09239
having the same binding site and higher affinity to HER2. Therefore, the specific accumulation might be excluded. periods in blood, and does not contribute to elevated off-target uptake. Taken this into account, the high uptake in lungs, liver and spleen may be attributed to the difference in amino acid composition. Elevated uptake of radiopeptides in these organs is usually associated with higher hydrophobicity. Indeed, evaluation using two scales of amino acid hydrophobicity [45, 44] suggests that Z HER2:342min is slightly more hydrophobic than PEP09239. Our previous studies on 3-helix Affibody molecules suggest that such minor difference might be enough to cause noticeable increase of hepatic uptake and/or hepatobiliary excretion [47] . We propose that substitution of non-binding residues (blue residues in Figure 1 ) to other charged or polar amino acids, such as serine, threonine, aspartate or glutamate, to increase the hydrophilicity of the Z HER2:342min scaffold, might improve its biodistribution profile and in vivo targeting potential. Other positions that could be substituted include the amino acids introduced to facilitate synthesis and cyclization (green residues in Figure 1) , such as the two amino acids flanking the intramolecular ligation site.
Two glycine residues were chosen to increase the flexibility and aid the cyclization reaction, but one could speculate that any small amino acid might be incorporated at the ligation site without losing cyclization ability or target affinity.
In conclusion, the use of NCL-cyclization enables production of a 2-helix Z HER2:342min
Affibody molecule that possesses high refolding capacity, permits site-specific radiolabelling, and has reasonably good affinity to its molecular target. Target specificity is preserved upon DOTA-mediated labeling with 111 In and 68 Ga, and enabled target-mediated accumulation in tumor xenografts. The presented 2-helix based binder does not perform as well as 3-helix binders with regard to target affinity and displays increased radioactivity uptake in lung, liver
and spleen compared to a disulfide-stabilized 2-helix Affibody. However, the 2-helix scaffold has a decreased total amount of amino acid residues, which facilitates production both from a synthesis and economical viewpoint. [27] Engfeldt T, Tran T, Orlova A, Widström C, Feldwisch J, Abrahmsen L, et al. Figure 1 . Schematic drawing of the Z HER2:342min scaffold prior to cyclization. A) Residues conferring HER2-binding specificity in red. B) Residues substituted to increase the solubility in blue. C) The substituted residues compared to the parental Z-domain. Binding residues are colored red, and substitutions to increase solubility are blue. Green marks residues that were introduced to facilitate synthesis and enable subsequent cyclization. Folded in C is the unmodified 3-helix Z-domain. D) Sequence of Z HER2:342min . Coloring is according to description above, and * indicates DOTA-conjugation site. Amino acid numbering is according to the original 3-helix scaffold. Representative SDS-PAGE analysis for identity of 68 Ga-labeled 2-helix scaffold DOTA-Z HER2:342min (1), free 68 Ga citrate (2) was used as a marker for low-molecular-weight compounds. The signal was measured as a digital light unit (DLU) in proportion to radioactivity in a given point of a lane in the SDS-PAGE gel. (Figure 3 ). Fitting binding LigandTracer curves to 1:2 interaction models suggests presence of two interactions, one stronger (7.3 nM) and one weaker (429 nM). The same measurement performed with 111 In-DOTA-Z HER2:342min also suggests presence of two interactions, one stronger (1.1 nM) and one weaker (107 nM). The 68 Ga-DOTA-Z HER2:342min sensorgram is shifted 100 signal units in the Y-direction to enhance visibility. In-DOTA-Z HER2:342min and 68 Ga-DOTA-Z HER2:342min in BALB/C nu/nu mice bearing SKOV-3 xenografts at 1 and 2 h p.i. The concentration of radioactivity is expressed as % ID/g, and presented as an average value from 4 animals ± standard deviation. Asterisk (*) indicate significant difference between 111 In and 68 Ga-labeled conjugates (p < 0.05 in paired Student's t-test).
Figure 8.
Comparison of tumor-to-organ ratios for 111 In-DOTA-Z HER2:342min and 68 Ga-DOTA-Z HER2:342min in BALB/C nu/nu mice bearing SKOV-3 xenografts at 1 and 2 h after injection. Asterisk (*) indicate significant difference between 111 In and 68 Ga-labeled conjugates (p < 0.05 in paired Student's t-test).
